Can vitamin D deficiency cause headaches?

Vitamin D Deficiency and Headaches

Yes, vitamin D deficiency is associated with increased headache frequency and severity, particularly in migraine patients, and correcting deficiency may reduce headache burden.

The Evidence for Association

The relationship between vitamin D deficiency and headaches is most robustly demonstrated in migraine populations. Multiple recent studies show that vitamin D deficiency (serum 25(OH)D <20 ng/mL) is highly prevalent in migraine patients (65-88%) and even higher in chronic migraine (80-92%) 1, 2, 3.

The most compelling evidence comes from studies showing:

• Inverse correlations between vitamin D levels and headache frequency: Lower vitamin D levels correlate with more frequent monthly headache days 1, 2
• Negative correlation with attack duration and severity: Deficient patients experience longer, more severe attacks with higher disability scores 1
• Worse headache characteristics: Patients with vitamin D deficiency have significantly higher rates of aura, photophobia/phonophobia, autonomic symptoms, and medication resistance 1

In children and adolescents aged 6-19 years, lower vitamin D levels were associated with higher headache likelihood, with this relationship being stronger in females and adolescents 4. For tension-type headaches, vitamin D deficiency is linked to higher incidence and longer episode duration, though not necessarily increased intensity 5.

Clinical Implications and Treatment

High-dose vitamin D supplementation (≥50,000 IU/week) reduces migraine attacks by 50-72% in deficient adults 3. However, this benefit is context-dependent—minimal improvement occurs in patients who are already vitamin D replete 3.

The Endocrine Society guidelines 6 establish that:

• Vitamin D deficiency causes generalized aches and pains in bones and muscles 6
• Treatment requires 50,000 IU of vitamin D2 once weekly for 8 weeks to correct deficiency 6
• Maintenance therapy of 50,000 IU every other week maintains levels between 35-50 ng/mL 6

Who Should Be Tested

While the 2024 Endocrine Society guideline 7 and U.S. Preventive Services Task Force 8 suggest against routine screening in the general population, testing is reasonable in patients with chronic or frequent headaches, particularly those with:

• Chronic or episodic migraine
• Dark skin pigmentation
• Limited sun exposure
• Obesity (BMI >30 kg/m²)
• Malabsorption conditions
• Use of anticonvulsants or other medications affecting vitamin D metabolism

The 2024 VA/DoD headache guideline 9 does not specifically address vitamin D testing or supplementation, reflecting the lack of high-quality randomized controlled trials in general headache populations.

Practical Approach

For patients with recurrent headaches:

1. Measure serum 25(OH)D if headaches are frequent (≥4 days/month) or chronic
2. Define deficiency as <20 ng/mL, insufficiency as 20-30 ng/mL 6
3. If deficient (<20 ng/mL): Prescribe vitamin D2 50,000 IU weekly for 8 weeks, then 50,000 IU every 2 weeks for maintenance 6
4. If insufficient (20-30 ng/mL): Consider 1,000-2,000 IU daily supplementation
5. Recheck levels at 3 months to ensure adequate response 10
6. Target level: 30-40 ng/mL for optimal health benefit 10

Important Caveats

• Obesity requires higher doses: Obese patients need 2-3 times more vitamin D (6,000-10,000 IU daily) to achieve and maintain adequate levels 6
• BMI may mediate the relationship: Body mass index accounts for approximately 21% of the association between vitamin D and headache risk 4, suggesting weight management may also be beneficial
• Combination therapy may enhance efficacy: Limited evidence suggests vitamin D combined with probiotics or topiramate may be more effective in refractory cases, though this requires validation 3
• Toxicity is rare: Occurs only at levels >200 ng/mL, well above therapeutic targets 8
• Calcium supplementation: Not routinely needed with vitamin D alone for headache management (unlike osteoporosis treatment)

The evidence strongly supports checking vitamin D levels in patients with frequent or chronic headaches and treating deficiency when identified, as this represents a modifiable risk factor with minimal harm and potential significant benefit.